Suppr超能文献

抗I型干扰素抗体是导致重症新型冠状病毒肺炎的一个原因。

Anti-type I interferon antibodies as a cause of severe COVID-19.

作者信息

Fajgenbaum David C, Hayday Adrian C, Rogers Angela J, Towers Greg J, Wack Andreas, Zanoni Ivan

机构信息

University of Pennsylvania.

King's College London; The Francis Crick Institute.

出版信息

Fac Rev. 2022 Jun 10;11:15. doi: 10.12703/r-01-0000010. eCollection 2022.

Abstract

COVID-19 ranges from asymptomatic through to respiratory failure and death. Although specific pre-existing conditions such as age and male sex have been associated with poor outcomes, we remain largely ignorant of the mechanisms predisposing to severe disease. In this study, the authors discovered that approximately 10% of 987 patients with life-threatening COVID-19 harbored neutralizing antibodies to Type I interferons (IFNs). They demonstrated that these antibodies could neutralize high concentrations of the corresponding IFN and could rescue SARS-CoV-2 infection from inhibition by IFN . Importantly, anti-IFN antibodies were associated with low levels of serum IFN. These observations suggest that disease severity in these individuals results from a failure to control SARS-CoV-2 replication because of antibody-mediated IFN inhibition. The study suggests specific treatments and diagnostics for this class of severe COVID-19.

摘要

新冠病毒病(COVID-19)的症状表现范围从无症状到呼吸衰竭及死亡。尽管诸如年龄和男性性别等特定的基础疾病已被发现与不良预后相关,但我们在很大程度上仍不清楚导致重症疾病的机制。在本研究中,作者发现,在987例危及生命的COVID-19患者中,约10%的患者体内存在针对I型干扰素(IFN)的中和抗体。他们证明,这些抗体能够中和高浓度的相应干扰素,并能使严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染免受干扰素的抑制。重要的是,抗干扰素抗体与血清干扰素水平较低有关。这些观察结果表明,这些个体的疾病严重程度是由于抗体介导的干扰素抑制导致无法控制SARS-CoV-2复制所致。该研究提示了针对这类重症COVID-19的特异性治疗方法和诊断手段。

相似文献

1
Anti-type I interferon antibodies as a cause of severe COVID-19.
Fac Rev. 2022 Jun 10;11:15. doi: 10.12703/r-01-0000010. eCollection 2022.
2
Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
J Clin Immunol. 2021 Apr;41(3):536-544. doi: 10.1007/s10875-021-00994-9. Epub 2021 Feb 22.
5
Type 1 interferon auto-antibodies are elevated in patients with decompensated liver cirrhosis.
Clin Exp Immunol. 2024 Feb 7;215(2):177-189. doi: 10.1093/cei/uxad119.
6
Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
J Clin Immunol. 2021 Jul;41(5):914-922. doi: 10.1007/s10875-021-01036-0. Epub 2021 Apr 13.
8
Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
J Virol. 2025 May 20;99(5):e0166824. doi: 10.1128/jvi.01668-24. Epub 2025 Mar 31.
9
Dysregulated early transcriptional signatures linked to mast cell and interferon responses are implicated in COVID-19 severity.
Front Immunol. 2023 May 16;14:1166574. doi: 10.3389/fimmu.2023.1166574. eCollection 2023.

引用本文的文献

1
Role of autoantibodies targeting interferon type 1 in COVID-19 severity: A systematic review and meta-analysis.
J Transl Autoimmun. 2023 Oct 14;7:100219. doi: 10.1016/j.jtauto.2023.100219. eCollection 2023 Dec.
2
Pin-Pointing the Key Hubs in the IFN-γ Pathway Responding to SARS-CoV-2 Infection.
Viruses. 2022 Sep 30;14(10):2180. doi: 10.3390/v14102180.

本文引用的文献

1
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200413119. doi: 10.1073/pnas.2200413119. Epub 2022 May 16.
2
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.
3
A dynamic COVID-19 immune signature includes associations with poor prognosis.
Nat Med. 2020 Oct;26(10):1623-1635. doi: 10.1038/s41591-020-1038-6. Epub 2020 Aug 17.
4
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Cell Host Microbe. 2020 Sep 9;28(3):455-464.e2. doi: 10.1016/j.chom.2020.07.005. Epub 2020 Jul 18.
5
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
6
Detection of interferon alpha protein reveals differential levels and cellular sources in disease.
J Exp Med. 2017 May 1;214(5):1547-1555. doi: 10.1084/jem.20161451. Epub 2017 Apr 18.
7
AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies.
Cell. 2016 Jul 28;166(3):582-595. doi: 10.1016/j.cell.2016.06.024. Epub 2016 Jul 14.
8
Human IFNAR2 deficiency: Lessons for antiviral immunity.
Sci Transl Med. 2015 Sep 30;7(307):307ra154. doi: 10.1126/scitranslmed.aac4227.
9
Immunology. An interferon paradox.
Science. 2013 Apr 12;340(6129):155-6. doi: 10.1126/science.1237568.
10
STAT2 deficiency and susceptibility to viral illness in humans.
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3053-8. doi: 10.1073/pnas.1220098110. Epub 2013 Feb 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验